12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TC-5619: Development discontinued

Targacept discontinued development of TC-5619 to treat ADHD after top-line data from a double-blind, U.S. Phase II trial in adults with inattentive-predominant ADHD showed that the compound missed the primary endpoint of improving inattention subscale scores of the CAARS-INV from baseline to week 4 vs. placebo. The company said placebo-treated patients consistently improved more than patients receiving TC-5619 across all study measures. The trial enrolled 175 patients, of which 153 completed the study, to receive once-daily 5 or 25 mg TC-5619 or placebo for 4 weeks. Data from a Phase...

Read the full 427 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >